RVU · RYVU THERAPEUTICS SPÓŁKA AKCYJNA · Investor Relations
Market Cap
368.54M PLN
Shares
23.12M
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Past events
| Date | Event | Type |
|---|---|---|
| 2025-12-07 | New clinical data on romaciclib (RVU120) at the ASH Annual Meeting 2025 | Shareholder meeting |
| 2025-10-02 | Discovery on Target 2025: ONCO Prime – A comprehensive platform for identification of novel synthetic lethal targets and drug combinations using patient-derived cells | Event |
| 2025-09-09 | EHA 2025: RVU120 enhances erythroid potential in MDS PDCs | Event |
| 2025-06-13 | RVU120 presentation at EHA 2025 | Presentation |
| 2025-06-12 | Webinar: The updated data on RVU120 presented at EHA 2025 | Event |
| 2025-06-10 | Emerging lymphoma therapies: exploring the drug-discovery process | Event |
| 2024-12-18 | RVU120 Progress and Data Update | Event |
| 2024-06-30 | Poster presentation – EHA 2024: June 2024 | Presentation |
| 2024-05-31 | Abstracts presentation — EHA 2024: May 2024 | Presentation |
Source: https://ryvu.com/investors